Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th
Anixa Biosciences, Inc. (NASDAQ: ANIX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines [Yahoo! Finance]
Anixa Biosciences, Inc. (NASDAQ: ANIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines